In vivo inhibition of reactive oxygen species (ROS) effectively reversed the decrease in hepatic‐activated CD4+ T cells induced by nonalcoholic fatty liver disease, subsequently delaying the progression of HCC.52 Here, CD4 is linked to metabolic dysfunction-associated steatotic liver disease.